Isomorphic Labs

What happens when cutting-edge AI meets decades of drug discovery expertise? Join Max Jaderberg, our Chief AI Officer, and Miles Congreve, our Chief Scientific Officer in a virtual fireside with Andrew Dunn at Endpoints News AI Day 2025 on 14 October, from 11:00-11:40am EDT. Join us to hear Max and Miles explain how AI and drug discovery come together in their work at Iso, and how our drug design engine will allow us to unlock new breakthroughs across many different therapeutic areas and modalities. Sign up now: bit.ly/4q0SHYX

In less than a week, our Chief Technology Officer Sergei Yakneen will open BioTechX EU, Europe's largest biotechnology conference, with his keynote: "AI Models from Atoms to Humans: the Era of Rational In Silico Drug Design." Join him in Basel on October 6th, at 9am CEST to explore how advanced AI is already reinventing drug discovery, from tackling program failures and precisely selecting targets, to navigating previously inaccessible chemical space.  He'll also outline his vision for a future where AI unlocks scientific insights and accelerates breakthroughs, getting us closer to solving all disease. We hope to see you there!  Find out more: bit.ly/42EClLB

Last week, our Chief Scientific Officer Miles Congreve participated in BioCentury Inc. Grand Rounds Europe in Cambridge, UK. He joined the "Small Compounds, Big Potential" panel, where he discussed the role of technology in accelerating and reducing the cost of molecule creation. Miles highlighted how innovations like structure-based drug design, protein structure prediction, generative AI, and in silico screening technologies enable chemists to develop potentially superior molecules more quickly and affordably, allowing them to pursue historically challenging targets, including those only previously addressable by biologics. He also emphasised the importance of collaborative efforts among academia, start-ups, and industry in advancing drug discovery and development.

Our Chief Technology Officer, Sergei Yakneen will be heading to BioTechX EU Congress in Basel on Monday, 6 October. BiotechX is Europe’s largest biotechnology conference and Sergei will open the event at 9am CEST with his keynote “AI Models from Atoms to Humans: the Era of Rational In Silico Drug Design”. AI is already helping us to understand disease like never before, but where are we going next? Sergei will explore tackling program failures like efficacy and safety, selecting the right targets, and going beyond individual proteins to examine complexes and molecular machines. He’ll set out a future where applying frontier AI will help unlock deeper scientific insights and faster breakthroughs with an ambition to solve all disease. If you are planning to attend, don't miss it. Find out more about the event here: bit.ly/42EClLB

“It is exciting to be able to have this generalisable drug design engine, which will allow us to tackle, not one, but a whole range of different cancers rather than just having to pick one program at a time.”  Our President, Colin Murdoch, joined Paige Winfield Cunningham on The Washington Post's Chasing Cancer series to discuss how we’re using our AI models at Isomorphic Labs to tackle some of the most challenging diseases, including cancers. Our ambitious approach aims to transform how quickly we can get drugs into the clinic and deliver medicines to the patients who need them most. Watch the full interview here: https://lnkd.in/gsrHF6WR

“I think in the fullness of time, when our platforms mature in the next couple of years, I’d like to see that [drug discovery timeline] cut down into a matter of months instead of years. That’s what I think is possible, perhaps even faster than that.” Demis Hassabis, interviewed by Tom Mackenzie on Bloomberg Tech Europe. Hear more from our CEO, Demis Hassabis, our Chief AI Officer, Max Jaderberg, and our Head of Medicinal Drug Design, Rebecca Paul, on the potential of Isomorphic Labs’ unified drug design engine to get medicines to patients faster and find solutions to some of the world’s most challenging disease targets.

“We’re not just trying to solve one disease or find one therapy…we’re trying to build a platform that can revolutionise the way we do drug discovery completely and discover hundreds of cures.” Our CEO, Demis Hassabis, our Chief AI Officer, Max Jaderberg, and our Head of Medicinal Drug Design, Rebecca Paul joined Tom Mackenzie on Bloomberg Tech Europe to discuss how we're leveraging frontier AI in groundbreaking ways to reimagine drug discovery and advance human health. At Isomorphic Labs, the ambition to solve all disease with the help of AI is immense. From our pioneering unified drug design engine to our interdisciplinary approach across multiple therapeutic areas and drug modalities, we're working to tackle some of the most challenging disease targets and transform the future of medicine. Watch the episode here: https://lnkd.in/eVi9_PyH

As part of the drug discovery process at Isomorphic Labs, the DMPK team works to deliver promising clinical candidates by advancing and employing our pioneering AI models to optimise compound design. Their interdisciplinary work takes compounds across a range of modalities from inception through to delivering preclinical candidates. Hear more from the team below, and learn about our open roles in DMPK on our website: bit.ly/424SMjZ

Congratulations to our Chief Scientific Officer, Miles Congreve, who has been featured in the TIME 100 AI list!  Miles’ experience at the forefront of drug discovery is instrumental in our work developing a generalisable AI drug design engine and tackling targets that have long been considered too difficult to pursue. See the full list here: https://lnkd.in/epF2E3N3 #TIME100AI

We were thrilled to welcome Sir David MacMillan, 2021 Nobel laureate in Chemistry and member of our Scientific Advisory Board, to Isomorphic Labs earlier this week. Our Chief Scientific Officer, Miles Congreve, led a fascinating fireside chat where Sir David shared his philosophy on pioneering new fields of science. He offered powerful advice on setting out to do things "you've no idea how to do," stressing the importance of starting with a fundamental question and keeping the ultimate goal at the forefront of your mind. Sir David, whose illustrious career has reshaped modern chemistry, also gave us a glimpse into his creative process, speaking about the art of visualising molecules in the mind's eye to help unlock novel solutions. An energising session that reinforced the curiosity, focus, and imagination required to tackle the biggest challenges in science and drug discovery. Thank you, Sir David, for inspiring our team!